Delving into the Latest Updates on JL-15003 with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms

Target-

Mechanism-

Therapeutic Areas

NeoplasmsNervous System DiseasesOther Diseases

Active Indication

Glioblastoma

Inactive Indication-

Originator Organization

Jecho Biopharmaceuticals Co., Ltd.

Active Organization

Jecho Biopharmaceuticals Co., Ltd.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价JL15003注射液治疗复发胶质母细胞瘤患者的安全性和耐受性。次要目的：初步评价JL15003对复发胶质母细胞瘤患者的疗效，为II期临床试验的给药剂量提供依据；观察JL15003在瘤内给药后的病毒脱落情况；探索复发胶质母细胞瘤患者肿瘤组织中与JL15003疗效相关的生物标志物。

[Translation]

Main purpose: Evaluate the safety and tolerability of JL15003 injection in the treatment of patients with recurrent glioblastoma. Secondary purpose: Preliminary evaluation of the efficacy of JL15003 in patients with recurrent glioblastoma, and provide a basis for the dosing of Phase II clinical trials; Observe the viral shedding of JL15003 after intratumoral administration; Explore biomarkers related to the efficacy of JL15003 in tumor tissues of patients with recurrent glioblastoma.

Start Date14 Oct 2022

Sponsor / Collaborator

Jecho Biopharmaceuticals Co., Ltd.

100 Clinical Results associated with JL-15003

Login to view more data

100 Translational Medicine associated with JL-15003

Login to view more data

100 Patents (Medical) associated with JL-15003

Login to view more data

100 Deals associated with JL-15003

Login to view more data